company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,82787000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,82787000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,19848000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,19848000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62939000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,30527000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26324000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1775000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58626000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4313000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4404000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1925000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2479000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1834000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,522000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1312000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1312000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1312000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100065000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,101217000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,131200000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q2,2009-04-01,2009-06-30,2010-08-04 16:33:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,80807000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,80807000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14970000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14970000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,65837000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28667000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26991000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,46000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,55704000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10133000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2880000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,332000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2548000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7585000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,945000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6640000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6640000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6640000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100331000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,101815000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,94900000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 12:46:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,84953000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,84953000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17412000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17412000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,67541000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30097000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,654000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,64751000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2790000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2429000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1426000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1003000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1787000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,636000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1151000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1151000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1151000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,101144000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,103720000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,115100000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 13:08:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,91950000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,91950000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14401000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14401000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,77549000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,37277000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35649000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1580000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,74506000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3043000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2635000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,171000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2464000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,579000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1056000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-477000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-477000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-477000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,101712000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,101834000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q2,2010-04-01,2010-06-30,2011-08-01 14:20:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,97750000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,97750000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18003000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18003000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,79747000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,38348000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,39366000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3972000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,81686000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1939000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3008000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,329000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2679000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4618000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-221952000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,217334000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,217334000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,217334000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,102110000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.13
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,131278000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.68
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,102000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q3,2010-07-01,2010-09-30,2011-10-31 14:26:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.13
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,101614000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,101614000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20469000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20469000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,81145000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,42098000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,42197000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,200000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,84495000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3350000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16474000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,97000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,489000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15888000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19238000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-7049000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12189000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12189000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12189000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,103093000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,125674000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,102900000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,109456000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,109456000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20796000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20796000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,88660000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,41037000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,45017000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,312000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,86366000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2294000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2163000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,240000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,22000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1901000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,393000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4764000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4371000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4371000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4371000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,110652000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,110743000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,109300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q1,2011-01-01,2011-03-31,2012-04-30 17:13:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,110631000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,110631000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,19263000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,19263000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91368000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,41015000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,52909000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,-3324000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,90600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,768000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2201000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,131000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,129000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1941000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1173000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3904000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5077000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5077000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5077000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,101500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,101500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,111114000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 15:30:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,113425000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,113425000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22445000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22445000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,90980000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,44880000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,58577000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3040000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,106497000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15517000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4064000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,114000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-264000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4214000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19731000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2078000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17653000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17653000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17653000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,110300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,110300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112290000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q3,2011-07-01,2011-09-30,2012-10-29 17:01:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,107846000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,107846000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,21519000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,21519000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,86327000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48491000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,57871000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,107762000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21435000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1877000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,23000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,173000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1681000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23116000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3619000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26735000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26735000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26735000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,112200000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,112200000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112122000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,116649000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,36000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,116685000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17105000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17105000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,99580000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,45248000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,73834000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2328000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,121410000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21866000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1947000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-229000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2176000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24006000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-34000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23972000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23972000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23972000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,114200000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,114200000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,115070000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q1,2012-01-01,2012-03-31,2013-04-29 15:07:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,124019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,124019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,23574000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,23574000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,100445000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,51539000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,77812000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2048000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,131399000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30954000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1925000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,638000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-176000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1463000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-32417000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-411000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32006000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32006000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32006000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,117912000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,117912000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,118500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q2,2012-04-01,2012-06-30,2013-07-29 14:01:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,128117000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,128117000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,24619000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,24619000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,103498000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,46337000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,66209000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1443000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,113989000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10491000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1837000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,442000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,125000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1270000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11761000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6404000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5357000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5357000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5357000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,133900000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,133900000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,123434000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q3,2012-07-01,2012-09-30,2013-10-28 13:17:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,131938000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-36000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,131902000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,26532000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,26532000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,105370000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,55049000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,84363000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,12898000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,152310000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-46904000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1930000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,512000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1736000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3154000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-50094000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2918000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-53012000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-53012000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-53012000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,120400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,120400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,120271000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,127928000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,127928000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,107428000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,51050000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,83743000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,5556000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,140349000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32921000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12145000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,317000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,228000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-44521000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-4711000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-39810000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-39810000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-39810000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,127969000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,127969000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,128400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q1,2013-01-01,2013-03-31,2014-05-02 12:15:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,136810000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,136810000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22567000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22567000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,114243000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,50656000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,85661000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,-2022000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,134295000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20052000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,603000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,487000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-123000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-239000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20291000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1242000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21533000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21533000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21533000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,139596000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,143600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 13:33:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,136874000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,136874000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,28054000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,28054000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,108820000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,61841000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,88064000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,9639000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,159544000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-50724000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2258000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,427000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,239000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1592000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-52316000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,704000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-53020000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-53020000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-53020000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,140796000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140796000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q3,2013-07-01,2013-09-30,2014-10-28 15:09:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,146873000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,146873000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17270000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17270000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,129603000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,71809000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,97312000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,11853000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,939000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,181913000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-52310000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8406000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,703000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,638000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7065000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-59375000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2615000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-61990000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-61990000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-61990000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,137800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.44
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,137800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,137755000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.44
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,151552000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,151552000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22816000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22816000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,128736000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,60069000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,86166000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,8957000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,155192000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26456000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9106000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,785000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,153000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8168000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-34624000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3491000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-38115000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-38115000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38115000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,143983000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,144157000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,146600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 11:35:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,191787000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,191787000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,31210000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,31210000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,160577000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,68089000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,107702000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3668000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,179459000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18882000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9895000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1196000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-147000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8846000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27728000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5774000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33502000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33502000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33502000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,146120000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,146351000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,145700000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 06:04:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,176549000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,176549000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,29920000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,29920000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,146629000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,74604000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,125686000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2636000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-67500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,135426000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11203000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9118000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1210000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-74000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7982000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3221000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-4224000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7445000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7445000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7445000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,147016000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,159304000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,148900000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q3,2014-07-01,2014-09-30,2015-11-02 09:36:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,229396000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,229396000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,38321000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,38321000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,191075000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,99394000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,141989000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,8448000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,249831000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-58756000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8523000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1869000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-327000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6981000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-65737000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4060000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-69797000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-69797000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-69797000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,146349000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.48
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,146349000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.47
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,145600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.48
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,202920000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,202920000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,30998000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,30998000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,171922000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,92806000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,142074000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2902000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,237782000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-65860000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9625000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,533000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,249000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8843000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-74703000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-7202000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-67501000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-67501000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-67501000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,157000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,157000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,157612000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 09:01:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.43
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,250135000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,250135000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,38063000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,38063000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,212072000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,101514000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,157901000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,16945000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,276360000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-64288000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10002000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,820000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-9073000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-18255000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-82543000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-554000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-81989000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-81989000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-81989000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,160800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,160800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,160406000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 09:30:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.51
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,208904000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,208904000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,34904000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,34904000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,174000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,94044000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,158713000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3116000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,255873000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-81873000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9447000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1158000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-281000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8570000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-90443000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,483000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-90926000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-90926000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-90926000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,160886000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.57
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,161134000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.6
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,159500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 09:01:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.57
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,227936000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,227936000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,48043000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,48043000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,179893000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,113907000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,176118000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,-40653000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,198700000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-369498000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,78574000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,101319000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9170000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1173000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-357000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8354000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,92965000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24348000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,68617000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,68617000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,68617000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,160025000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.44
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,160025000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,160600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.44
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,236736000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,236736000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,43118000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,43118000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,193618000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,105300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,158793000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,10442000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,274535000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-80917000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9843000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1436000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,198000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8209000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-89126000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6075000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-83051000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-83051000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-83051000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,162800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,162800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,161548000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:42:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.51
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,300131000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,300131000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,51617000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,51617000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,248514000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,109577000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,167039000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,-54414000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,599118000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,821320000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-572806000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9944000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1222000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1417000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-10139000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-582945000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-163931000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-419014000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-419014000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-419014000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,162400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.58
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,162400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.58
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,162587000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q2,2016-04-01,2016-06-30,2017-08-02 17:31:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.58
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,279896000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,279896000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,50738000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,50738000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,229158000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,118758000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,160831000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,9654000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,289243000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-60085000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9980000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1529000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1723000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6728000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-66813000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-29388000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37425000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37425000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-37425000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,167714000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,167714000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,170100000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q3,2016-07-01,2016-09-30,2017-10-31 16:13:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,300091000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,300091000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,64147000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,64147000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,235944000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,142958000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,175242000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,7365000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,325565000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-89621000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9732000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2762000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4425000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2545000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-92166000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1446000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-90720000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-90720000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-90720000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,165985000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,166219000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,165800000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,303745000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,303745000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,50006000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,50006000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,253739000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,120019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,145003000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,8925000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,273947000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20208000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10119000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2549000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3472000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4098000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24306000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8016000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16290000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16290000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16290000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,172710000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,172710000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,181000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 06:06:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,317448000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,317448000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,56305000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,56305000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,261143000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,143505000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,143039000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,13411000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,299955000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38812000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10040000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2763000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,543000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6734000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-45546000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8713000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36833000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36833000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-36833000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,175400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,175400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,174374000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 06:06:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,334148000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,334148000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,59480000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,59480000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,274668000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,130532000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,154103000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3760000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,288395000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13727000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10884000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3723000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,267000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6894000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20621000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8094000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12527000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12527000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12527000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,179000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,179000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,175103000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q3,2017-07-01,2017-09-30,2018-10-26 06:06:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,358305000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,358305000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,75995000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,75995000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,282310000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,160280000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,168608000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,20375000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-125000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,224263000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,58047000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11664000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4527000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3688000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3449000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,54598000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,105990000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-51392000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-51392000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-51392000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,174427000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,174427000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,174700000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,373447000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,373447000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,82333000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,82333000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,291114000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,138336000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,183948000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,13202000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,335486000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-44372000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11562000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5302000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-172000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6432000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-50804000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6655000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-44149000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44149000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-44149000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,175932000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,176150000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,176600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q1,2018-01-01,2018-03-31,2019-04-29 06:08:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,372845000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,372845000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,79019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,79019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,293826000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,153280000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,175582000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,10227000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-20000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,319089000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25263000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12225000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5462000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2849000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3914000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29177000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-12385000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16792000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16792000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16792000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,176873000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,186600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,186600000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 06:10:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,391706000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,391706000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,78893000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,78893000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,312813000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,148566000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,161408000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,18580000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,328554000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15741000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12131000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5870000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2589000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3672000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19413000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6793000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12620000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12620000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12620000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,177481000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,177481000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,180300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q3,2018-07-01,2018-09-30,2019-10-29 12:58:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,353214000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,353214000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,75019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,75019000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,278195000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,164171000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,175390000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,6782000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-30000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,316343000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38148000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7746000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5644000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3061000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5163000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-43311000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-39661000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3650000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3650000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3650000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,177061000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,177268000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,175500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,400745000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,400745000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,89182000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,89182000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,311563000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,162158000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,183591000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,19765000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,365514000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-53951000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6727000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,6113000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1608000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,994000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-52957000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3516000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-56473000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-56473000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-56473000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,178271000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.32
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,178271000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.32
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,176500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 13:54:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.32
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,387763000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,387763000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,77436000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,77436000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,310327000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,160754000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,185641000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,20286000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-15000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,351681000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-41354000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6866000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5855000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,470000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-541000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-41895000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-4460000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37435000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37435000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-37435000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,179048000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,178300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,178300000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 06:10:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,461097000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,461097000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,96949000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,96949000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,364148000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,170112000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,172963000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,17063000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,360138000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4010000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2937000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4789000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3960000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5812000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9822000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-45214000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,55036000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,55036000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,55036000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,179289000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.31
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,185924000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.3
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,177500000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 07:36:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.31
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,454443000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,454443000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,95899000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,95899000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,358544000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,187900000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,172812000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,16994000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-10000000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,367706000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9162000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6930000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5404000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,907000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-619000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9781000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-24805000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15024000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15024000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15024000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,179039000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.09
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,179039000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,183400000.0
Biomarin Pharmaceutical Inc,BMRN,NSLL8ITTRR0J5HEMR848,0001048477,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.09
